2-Amino-1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalin | 52679-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-Amino-1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalin
• 英文别名: 7-methoxy-1,1-dimethyl-3,4-dihydro-2H-naphthalen-2-amine
• CAS: 52679-89-7
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: XUEZQNCODZZZHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Amino-1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalin 在 盐酸 、 potassium nitrate 、 三乙胺 、 三氟乙酸酐 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙二醇乙醚 、 二氯甲烷 、 水 、 乙腈 为溶剂， 100.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 N2-(6-amino-3-methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies

  摘要：

  A series of novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety were synthesized and evaluated for their anti-anaplastic lymphoma kinase (ALK) activities using enzymatic and cell-based assays. Among the compounds synthesized, compound 17b showed promising pharmacological results in in vitro, ex vivo, and pharmacokinetic studies. An in vivo efficacy study with compound 17b demonstrated highly potent inhibitory activity in H3122 tumor xenograft model mice. A series of kinase assays showed that compound 17b inhibited various kinases including FAK, ACK1, FGFR, RSK1, IGF-1R, among others, thus demonstrating its potential for synergistic anti-tumor activity and development as a multi-targeted non-small cell lung cancer (NSCLC) therapy. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.02.052
• 作为产物：
  描述：

  7-甲氧基-1,1-二甲基-3,4-二氢萘-2(1H)-酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 2-Amino-1,1-dimethyl-7-methoxy-1,2,3,4-tetrahydronaphthalin
  参考文献：
  名称：

  Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies

  摘要：

  A series of novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety were synthesized and evaluated for their anti-anaplastic lymphoma kinase (ALK) activities using enzymatic and cell-based assays. Among the compounds synthesized, compound 17b showed promising pharmacological results in in vitro, ex vivo, and pharmacokinetic studies. An in vivo efficacy study with compound 17b demonstrated highly potent inhibitory activity in H3122 tumor xenograft model mice. A series of kinase assays showed that compound 17b inhibited various kinases including FAK, ACK1, FGFR, RSK1, IGF-1R, among others, thus demonstrating its potential for synergistic anti-tumor activity and development as a multi-targeted non-small cell lung cancer (NSCLC) therapy. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.02.052

文献信息

• ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0579833B1

  公开（公告）日：1997-08-20
• HIROSE NORIYASU; KURIYAMA SHIZUO; FUJIMOTO MASATOSHI; TOYOSHIMA SHOJI, YAKUGAKU DZASSI, YAKUGAKU ZASSNI, J. PHARM. SOS. JAR. <YKKZ-AJ>, 1976, 96+
  作者：HIROSE NORIYASU、 KURIYAMA SHIZUO、 FUJIMOTO MASATOSHI、 TOYOSHIMA SHOJI

  DOI：——

  日期：——
• Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies
  作者：Dawn Song、Minji Lee、Chi Hoon Park、Sunjoo Ahn、Chang Soo Yun、Chong Ock Lee、Hyoung Rae Kim、Jong Yeon Hwang

  DOI：10.1016/j.bmcl.2016.02.052

  日期：2016.4

  A series of novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety were synthesized and evaluated for their anti-anaplastic lymphoma kinase (ALK) activities using enzymatic and cell-based assays. Among the compounds synthesized, compound 17b showed promising pharmacological results in in vitro, ex vivo, and pharmacokinetic studies. An in vivo efficacy study with compound 17b demonstrated highly potent inhibitory activity in H3122 tumor xenograft model mice. A series of kinase assays showed that compound 17b inhibited various kinases including FAK, ACK1, FGFR, RSK1, IGF-1R, among others, thus demonstrating its potential for synergistic anti-tumor activity and development as a multi-targeted non-small cell lung cancer (NSCLC) therapy. (C) 2016 Elsevier Ltd. All rights reserved.